Straits Times Index
3,320.22 -6.06 (-0.18%) Nikkei
39,667.07 +493.92 (+1.26%) Hang Seng
18,118.38 +45.48 (+0.25%) FTSE 100
8,247.79 -33.76 (-0.41%) Bitcoin USD
61,564.52 +415.65 (+0.68%) CMC Crypto 200
1,278.43 -5.35 (-0.42%)
STOK240816C00010000
- Business Wire
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
BEDFORD, Mass., June 18, 2024--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that, effective on June 17, 2024, the company granted stock options to purchase an aggregate of 10,400 shares of common stock to one new employee, as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4).
- Simply Wall St.
We Think Stoke Therapeutics (NASDAQ:STOK) Can Afford To Drive Business Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
- Business Wire
Stoke Therapeutics to Present at Upcoming Investor Conferences in June
BEDFORD, Mass., June 03, 2024--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will present at the following upcoming investor conferences:
